Page 6 - Dermavant Sciences News Today

Approved for mild, moderate and severe psoriasis with no restrictions on duration of use or body surface, see why VTAMA Cream, 1%, may help your patients.

- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician

Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.

- Tapinarof demonstrated continued improvements for up to 52 weeks in efficacy outcomes, quality of life measures, and tolerability scores with no associated tachyphylaxis - Tapinarof was well-tolerated

- Two posters will present data across secondary efficacy outcomes, quality of life and tolerability scores of tapinarof cream 1% once daily - Dermavant Sciences, a clinical-stage biopharmaceutical

Patients from PSOARING 3 who completed the survey preferred tapinarof to prior topical treatments with 81.7% considering it more effective Dermavant Sciences, a clinical-stage biopharmaceutical company

- Patient satisfaction results from tapinarof long-term extension study for the treatment of plaque psoriasis in adults to be presented - Dermavant Sciences, a clinical-stage biopharmaceutical company

Healio Psoriatic Disease | Topical steroids have remained a mainstay first-line treatment for psoriasis, but two new drugs in development aim to revolutionize how topical drugs are used in treatment of the disease.“We’ve had a decent amount of minor innovation in psoriasis,” Mark G. Lebwohl, MD, dean for clinical therapeutics and chair emeritus of the Kimberly and Eric J. Waldman Department of Dermatology

Benefits of treatment with tapinarof 1% were seen even with intermittent use in the extension trial.

Psoriasis Market to Exhibit Promising Growth at a CAGR of 5.6% in the United States during the Study Period [2018-2030], States DelveInsight LAS VEGAS, May 11, 2021 /PRNewswire/ -- DelveInsights " Psoriasis Market" report provides a thorough comprehension of the Psoriasis, historical and forecasted epidemiology, and the Psoriasis market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Psoriasis market report also proffers an analysis ...